Business Context and Reporting Period
This Form 8-K was filed by Frequency Therapeutics, Inc. (not Korro Bio, Inc.) on December 10, 2021. The registrant is a Delaware corporation with its principal executive offices in Lexington, MA. The filing reports the entry into a material definitive agreement regarding an equity distribution program.
Key Financial Metrics
This filing does not contain standard financial performance metrics such as revenue, profit, cash flow, margins, or debt levels. The primary financial data point disclosed is the authorization of an equity offering with aggregate gross sales proceeds of up to $125.0 million. The company will pay the sales agent a commission of 3.0% of the gross proceeds.
Material Changes
The material change reported is the execution of an Equity Distribution Agreement with Oppenheimer & Co. Inc. on December 10, 2021. This agreement establishes an "at the market" equity offering program allowing the company to sell shares of its common stock from time to time. Sales will be conducted pursuant to the company's existing shelf registration statement on Form S-3.
Guidance, Outlook, and Risks
- Management Commentary: The company retains control over sale parameters, including the number of shares, timing, daily volume limitations, and minimum price thresholds.
- Termination Rights: The agreement may be terminated by either party upon ten days' prior notice, or immediately under certain circumstances, including a material adverse change in the company.
- Risks: The filing includes standard disclaimers that the report does not constitute an offer to sell securities in jurisdictions where such an offer would be unlawful.
Investor Verification Checklist
- Verify the company name is Frequency Therapeutics, Inc. (Ticker: FREQ), as the input metadata incorrectly referenced "Korro Bio, Inc."
- Confirm the total authorized offering size of $125.0 million and the 3.0% commission fee.
- Review the referenced shelf registration statement (File No. 333-250099) for existing share availability.
- Check subsequent filings to determine if and when shares were actually sold under this agreement.